Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa

NCT06213506 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06213506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06213506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2024
Completion date
August 6, 2026
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salmonella infections